We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

95 hedge funds and large institutions have $85.9M invested in Palvella Therapeutics in 2020 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 30 increasing their positions, 31 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

0.03% more ownership

Funds ownership: 0.81% → 0.84% (+0.03%)

3% less repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 31

2% less funds holding

Funds holding: 97 → 95 (-2)

11% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 18

33% less capital invested

Capital invested by funds: $129M → $85.9M (-$42.6M)

Holders
95
Holders Change
-2
Holders Change %
-2.06%
% of All Funds
2.09%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
16
Increased
30
Reduced
31
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
CA
Corriente Advisors
Texas
+$5.61M
2
WP
Woodline Partners
California
+$3.29M
3
SB
Samsara BioCapital
California
+$2.89M
4
ACM
Aquilo Capital Management
California
+$1.92M
5
BI
BVF Inc
California
+$1.65M

Top Sellers

1
EC
EcoR1 Capital
California
-$7.15M
2
OAM
Oxford Asset Management
United Kingdom
-$1.3M
3
Morgan Stanley
Morgan Stanley
New York
-$1.29M
4
N
Nuveen
North Carolina
-$719K
5
MWNA
Marshall Wace North America
New York
-$701K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$13.4M +$1.65M +6,536 +10%
ACM
2
Aquilo Capital Management
California
$12.7M +$1.92M +7,609 +12%
BlackRock
3
BlackRock
New York
$7.66M -$150K -595 -1%
CS
4
Candriam SCA
Luxembourg
$5.27M +$252 +1 +0%
Renaissance Technologies
5
Renaissance Technologies
New York
$4.21M -$438K -1,738 -7%
CA
6
Corriente Advisors
Texas
$4.06M +$5.61M +22,274 New
SB
7
Samsara BioCapital
California
$3.69M +$2.89M +11,450 +130%
TCM
8
Tekla Capital Management
Massachusetts
$3.3M – – –
Citadel Advisors
9
Citadel Advisors
Florida
$2.76M +$86.7K +344 +2%
Vanguard Group
10
Vanguard Group
Pennsylvania
$2.47M +$166K +658 +5%
WP
11
Woodline Partners
California
$2.38M +$3.29M +13,063 New
State Street
12
State Street
Massachusetts
$2.11M -$187K -744 -6%
OFM
13
Omega Fund Management
Massachusetts
$1.71M – – –
Geode Capital Management
14
Geode Capital Management
Massachusetts
$1.64M +$288K +1,141 +15%
Acadian Asset Management
15
Acadian Asset Management
Massachusetts
$1.49M +$159K +630 +8%
Northern Trust
16
Northern Trust
Illinois
$1.25M +$44.4K +176 +3%
PHP
17
Parkman Healthcare Partners
Connecticut
$1.14M -$386K -1,533 -20%
Citigroup
18
Citigroup
New York
$945K +$1.27M +5,055 +4,044%
Morgan Stanley
19
Morgan Stanley
New York
$912K -$1.29M -5,137 -51%
Goldman Sachs
20
Goldman Sachs
New York
$759K +$97.3K +386 +10%
PIM
21
Platinum Investment Management
Australia
$693K – – –
Jacobs Levy Equity Management
22
Jacobs Levy Equity Management
New Jersey
$687K +$126K +499 +15%
LOAMU
23
Lombard Odier Asset Management (USA)
New York
$684K -$315K -1,250 -25%
RPAM
24
Rhenman & Partners Asset Management
Sweden
$684K – – –
EC
25
EcoR1 Capital
California
$602K -$7.15M -28,388 -90%
1
2 3 4 5

PVLA Hedge Fund Activity: Q1 2020 in Review

95 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q1 2020, worth a combined $85.9M — down 33% from $129M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of PVLA and 16 opened new positions — a net loss of 2 holders — while 31 trimmed existing stakes and 30 added.

The largest buyer was Corriente Advisors, opening a new position worth an estimated $5.61M. The largest seller was EcoR1 Capital, cutting an estimated $7.15M.

  • 95 institutional investors held Palvella Therapeutics (PVLA) as of Q1 2020, down from 97 in Q4 2019.
  • Funds reported $85.9M of Palvella Therapeutics stock for Q1 2020, down 33% quarter-over-quarter.
  • 16 funds opened new Palvella Therapeutics positions in Q1 2020 and 18 closed out, a net change of -2 holders.
  • The largest Palvella Therapeutics buyer in Q1 2020 was Corriente Advisors, an estimated $5.61M added.
  • The largest Palvella Therapeutics seller in Q1 2020 was EcoR1 Capital, an estimated $7.15M sold.

Based on aggregated 13F filings for Q1 2020.